Linagliptin Hexal

Linagliptin, the active ingredient in Linagliptin Hexal, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when used as part of a comprehensive diabetes treatment plan.

GNH USA supplies Linagliptin Hexal as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide in accordance with EU regulatory standards.

Linagliptin is a DPP‑4 inhibitor used in the treatment of type 2 diabetes mellitus.

- Type 2 diabetes mellitus (monotherapy): reduces blood glucose when used alone. - Type 2 diabetes mellitus (combination therapy): enhances glycaemic control when added to metformin, sulfonylureas or insulin. - Type 2 diabetes mellitus (adjunct to lifestyle): supports diet and exercise in achieving target HbA1c.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract inflammation. - Headache: transient, mild to moderate intensity. - Dizziness: occasional light‑headed sensation. - Gastrointestinal upset: includes nausea, abdominal discomfort. - Back pain: musculoskeletal discomfort. - Arthralgia: joint pain without swelling.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe hypersensitivity: rash, angioedema, or anaphylaxis. - Hepatic injury: abnormal liver function tests. - Bullous skin reactions: blistering dermatoses. - Severe allergic reactions: including Stevens‑Johnson syndrome. - Angioedema: swelling of face, lips, or airway.

Linagliptin should be used with clinical caution in the following situations: - Renal impairment: assess renal function before initiating therapy. - Hepatic impairment: monitor liver enzymes regularly. - Hypersensitivity: discontinue if rash, angioedema, or severe allergic reaction occurs. - Pregnancy and lactation: only if clearly needed after risk‑benefit evaluation. - Cardiovascular disease: monitor for any unexpected cardiac events. - Store at ambient temperature: keep below 25 °C, retain in the original packaging, and protect from moisture and light.

Linagliptin may interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure. - Strong CYP3A4 inducers (e.g., rifampicin): may reduce linagliptin exposure. - Concurrent insulin secretagogues (e.g., sulfonylureas): heightened risk of hypoglycaemia.

Moderate Interactions (Monitor Closely): - Diuretics: may affect blood glucose monitoring accuracy. - Rifampin (moderate inducer): may lower linagliptin plasma levels. - Antihypertensives: observe blood pressure changes when combined with improved glycaemic control.